Quidel to Hold Second Quarter 2018 Financial Results Conference Call on August 7, 2018
July 17 2018 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will report second quarter 2018
financial results after market close on Tuesday, August 7,
2018.
Following the release of results, Douglas Bryant, president and
chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to
discuss the results and answer questions. During the conference
call, the company will also discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and
enter the audience pass code 485-7326.
A live webcast of the call can be accessed on the Investor
Relations section of the Quidel website (http://ir.quidel.com). The
website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 8:00 p.m. Eastern Time
(5:00 p.m. Pacific Time) on August 7, 2018 by dialing 855-859-2056
from the U.S., or by dialing 404-537-3406 for international
callers, and entering pass code 485-7326.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's recently
acquired Triage® system of tests comprises a comprehensive test
menu that provides rapid, cost-effective treatment decisions at the
point-of-care (POC), offering a diverse immunoassay menu in a
variety of tests to provide healthcare providers with diagnostic
answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I
and qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180717005921/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2023 to Aug 2024